Ranibizumab improves BCVA in patients with myopic choroidal neovascularization
ORLANDO, Fla. — Best corrected visual acuity improved in patients with myopic choroidal neovascularization treated with ranibizumab, according to the RADIANCE study presented here at the Association for Research in Vision and Ophthalmology meeting.
“Regardless of baseline ocular characteristics, ranibizumab treatment guided by disease activity criteria led to similar and effective BCVA improvements across all the subgroups analyzed,” Nicolas Leveziel, MD, PhD, and colleagues said in the poster.
Two hundred seventy-seven patients with visual impairment due to myopic CNV were randomized into three groups: 106 patients received 0.5 mg Lucentis (ranibizumab, Genentech) treatment guided by visual acuity stabilization; 116 patients received ranibizumab 0.5 mg treatment guided by disease activity; and 55 patients received verteporfin photodynamic therapy, the study said.
Patients treated with ranibizumab guided by disease activity showed a 14.4 letter increase in BCVA. Ranibizumab shows good safety and efficacy with regard to BCVA, Leveziel told Ocular Surgery News.
“Patients with higher baseline BCVA had to use more injections and patients with lower BCVA baselines needed to use [fewer] injections,” Leveziel said.
All groups reached similar improvements in BCVA at month 12.
Disclosure: Leveziel is a consultant for and receives financial support from Novartis, Bayer Healthcare Pharmaceuticals, Thea, Adnan, Alcon, Allergan, Heidelberg Engineering, Oculogics, Roche and ThromboGenics.